
CJC-1295 No DAC
10 mg
Modified GHRH (1–29) analog without albumin binding, used as a short-duration receptor reference.
Free U.S. shipping $175+

Ipamorelin is a synthetic pentapeptide that acts as an agonist at the growth hormone secretagogue receptor (GHS-R1a), the same receptor engaged by the endogenous peptide ghrelin.
It is widely used in laboratory research because published characterization describes it as more selective than earlier secretagogue peptides, which makes it useful for isolating GHS-R1a-mediated signaling from other endocrine effects in preclinical models.
For research use only — not for human or animal consumption.
Supplied solely for legitimate laboratory and research purposes. Not for medical or veterinary use, diagnosis, treatment, or prevention of disease.
Analytical values reflect per-lot documentation and appear once a batch is released.
Topics reflect published preclinical and in vitro research. Reference only — not a claim of clinical outcomes.
Ipamorelin was described in the late 1990s as one of the first selective growth hormone secretagogues, distinguishing it from broader-acting members of the GHRP series.
It is now a standard reference peptide in ghrelin-receptor research and is commonly paired with GHRH analogs such as CJC-1295 in co-treatment protocols.

10 mg
Modified GHRH (1–29) analog without albumin binding, used as a short-duration receptor reference.

5/5 mg
Combined GHRH analog and secretagogue receptor agonist preparation for dual-input pituitary research.

5 mg
GHRH analog with Drug Affinity Complex modification for extended-duration receptor research.

10 mg
Second-generation growth hormone releasing peptide studied as a ghrelin receptor agonist reference.